跳转到内容

Phase III Clinical Trial Protocol of Afuresertib for Prostate Cancer

Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) („LAE201“)in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment. Laekna initiated a Phase II clinical trial of the multi-region clinical trial of the study of LAE201 in the U.S. in June 2021, and South Korea in September 2022. The trial is an open-label, dose-escalation and dose expansion study to assess the efficacy and safety of the combination candidate. The study demonstrated promising treatment benefit for mCRPC patients. As of Nov 21, 2023, 40 patients who progressed on 1–3 lines of standard treatments, including at least 1 line of abiraterone, or the second generation… 

Phase III Clinical Trial Protocol of Afuresertib for Prostate Cancer

Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) („LAE201“)in patients with metastatic castration-resistant prostate cancer (mCRPC) following standard of care (SOC) treatment. Laekna initiated a Phase II clinical trial of the multi-region clinical trial of the study of LAE201 in the U.S. in June 2021, and South Korea in September 2022. The trial is an open-label, dose-escalation and dose expansion study to assess the efficacy and safety of the combination candidate. The study demonstrated promising treatment benefit for mCRPC patients. As of Nov 21, 2023, 40 patients who progressed on 1–3 lines of standard treatments, including at least 1 line of abiraterone, or the second generation… 

First US patient in cardiac amyloidosis trial

Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The team is also the first to in the U.S. to screen for the trial. „If a patient qualifies for the clinical trial, it will allow us to provide a treatment option when they receive an amyloidosis diagnosis without having to travel outside of the region for care,“ said Dr. Carry. „Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life.“ Cardiac amyloidosis is caused by protein buildup between the muscle cells of the heart, increasing the thickness of the heart. As these proteins build up, the heart becomes thicker and struggles to pump blood. Over time as the heart thickens, heart failure develops.… 

What makes a public health campaign successful

The highest performing countries across public health outcomes share many drivers that contribute to their success. That’s the conclusion of a new study published May 9  in the open-access journal PLOS Global Public Health by Dr. Nadia Akseer, an Epidemiologist-Biostatistician at Johns Hopkins Bloomberg School of Public Health and co-author of the study and colleagues in the Exemplars in Global Health (EGH) program. In the new study, the researchers systematically analyzed 31 previous EGH studies across six topics, including under-five child mortality, childhood stunting, community health workers (CHW), vaccine delivery, COVID-19 response, and newborn and maternal mortality reduction. The studies included data from 19 countries in Africa, Latin America, Asia, and the Caribbean. The EGH team looked for common themes and findings in these countries that resulted in programmatic success. In general, the drivers that were seen most often in… 

超加工食品: 过早死亡风险增加

Higher consumption of most ultra-processed foods is linked to a slightly higher risk of death, with ready-to-eat meat, poultry, and seafood based products, sugary drinks, dairy based desserts, and highly processed breakfast foods showing the strongest associations, finds a 30-year US study in The BMJ today. The researchers say not all ultra-processed food products should be universally restricted, but that their findings “provide support for limiting consumption of certain types of ultra-processed food for long term health.” Ultra-processed foods include packaged baked goods and snacks, fizzy drinks, sugary cereals, and ready-to-eat or heat products. They often contain colours, emulsifiers, flavours, and other additives and are typically high in energy, added sugar, saturated fat, and salt, but lack vitamins and fibre. Mounting evidence links ultra-processed foods to higher risks of obesity, heart disease, diabetes and bowel cancer, but few long term… 

Telomere findings offer new insights for cancer treatments

A new study led by University of Pittsburgh and UPMC Hillman Cancer Center researchers shows that an enzyme called PARP1 is involved in repair of telomeres, the lengths of DNA that protect the tips of chromosomes, and that impairing this process can lead to telomere shortening and genomic instability that can cause cancer. PARP1’s job is genome surveillance: When it senses breaks or lesions in DNA, it adds a molecule called ADP-ribose to specific proteins, which act as a beacon to recruit other proteins that repair the break. The new findings, published today in Nature Structural & Molecular Biology, are the first evidence that PARP1 also acts on telomeric DNA, opening up new avenues for understanding and improving PARP1-inhibiting cancer therapies. O’Sullivan hypothesizes that ADP-ribose affects telomere integrity by disrupting a protective structure called shelterin that safeguards telomeres, but more… 

Hot Water Potential Solution to Prostate Cancer

A clinical trial tests if hot water vapor can attack cancer cells, in new non-surgical approach to prostate cancer treatment. LAGUNA HILLS, Calif., May 7, 2024 /- MemorialCare Cancer Institute at Saddleback Medical Center is the only location in Orange County – and one of only two in California – to offer a new, innovative way to treat prostate cancer patients with water vapor. This study, VAPOR 2, utilizes a minimally invasive and nonsurgical procedure that employs water vapor to target and destroy the walls of the cancer cells while minimizing damage to the surrounding healthy prostate tissue. With the VAPOR 2 study, water vapor technology applies the thermal energy stored in a few drops of sterile water through a transurethral procedure – entering through the urethra – to get directly to the cancerous tissue. The heat from the water… 

Non-pharmaceutical ADHD clinical trial seeking pediatric patients

Innosphere Engineering Ltd (Innosphere or the Company), a medical device company developing non-pharmaceutical treatments for ADHD, is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation (tRNS) on ADHD symptoms in pediatric patients (7 – 12 years). „Novostim 2 uses a non-invasive technique where a weak signal is applied to the brain, subtly enhancing brain activity. It is like a buzzing sensation to the brain that may activate some regions important for attention by making your brain’s natural activities change or become more efficient,“ says Dr. Cesar A. Soutullo, MD, PhD, Vice Chair and Chief, Child & Adolescent Psychiatry and Director of the ADHD Outpatient Program at McGovern Medical School, UTHealth Houston. „Following positive and encouraging results from small trials, we are testing… 

mRNA药物旨在降低血液中的脂质

根据布莱根妇女医院(麻省总医院联合医疗系统创始成员)研究人员领导的一项安慰剂对照、双盲研究,一种实验性疗法可能会进一步降低血液中的甘油三酯。研究结果在2024年美国心脏病学会科学会议及博览会(American College of Cardiology’s 2024 Annual Scientific Session & Expo)上公布,并同时发表在《新英格兰医学杂志》(New England Journal of Medicine)上。在这项研究中,154名接受了中度至重度高甘油三酯血症脂质治疗的成年人被随机分配接受50毫克Olezarsen、80毫克Olezarsen或安慰剂。Olezarsen是一种反义寡核苷酸,通过靶向APOC3基因的mRNA来抑制APOC3,该基因与甘油三酯水平升高有关。该皮下注射药物每四周给药一次,持续一年。与安慰剂相比,50毫克剂量的Olezarsen将甘油三酯水平降低了49%,而… 

Headlands Research with Pfizer to Improve Diversity in Clinical Trials

SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ — Headlands Research, a leading multinational network of clinical trial sites, today announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse demographics. „As an organization, we have been committed to diversity in clinical trials since day one,“ said Kyle Burtnett, CEO of Headlands Research. „Our partnership with Pfizer has been a critical component in our continued goal of making clinical research accessible to all.“ Home